New treatment was then initiated, but the patient died after about 5 months. The second patient (panel B), which had a normal serum IGF-I (51 ng/ml) concentration at diagnosis, did not respond to treatment and with the exception of an IGF-I reduction observed 10 months after starting NCT-501 therapy, he showed only slight modifications of both serum variables during the course of disease. Discussion and conclusion MM evolution has been shown to be strongly conditioned by angiogenic mechanisms in terms of growth and therapy sensitivity. Several authors tried to explain how angiogenic cytokines [4, 31] may work influencing the MM cells; consequently, in the recent years, the presence

and quantity of several angiogenic factors, their inducers and their signalling mediators have been documented in an effort

to explore the possibility to use them as diagnostic, monitoring or prognostic markers of disease evolution and therapy sensitivity. Despite this bulk of information, clear indications have not been completely gained and some different contrasting results have been published [4, 8, 9, 32–34]. In general, angiogenic mediators (VEGF, basic FGF, TGF-beta1, TNF-alpha) have been found to be increased in MM patients and often significantly correlated each to the others [8]. Sometimes, they were also stage related, although not all the reports were consistent in this field. Angiogenic factors also show different behaviours under treatment. Interestingly, while

conventional therapy (melphalan plus prednisolone) PD184352 (CI-1040) reduced the serum concentrations of these factors [35], an anti-angiogenic selleck compound therapy based on thalidomide plus dexamethasone was accompanied by increase of the same factors in the responder subjects [4, 34]. Another molecule involved in MM biology is IGF-I, a mediator with cytokine (locally)/hormone (in the general circulation) activity [36], known to be a growth promoter for several tumours, including MM, acting through its anti-apoptotic/proliferative [16, 19, 37] effects and interaction with angiogenic factors, such as the anti-proliferative TGF-beta1 [38]. Surprisingly, serum data regarding IGF-I and MM are very scarce and partially contrasting [39, 40] although IGF-I is suspected to be able to transform MGUS in MM [41]. Previous data on B-cell chronic lymphocytic leukaemia have found a clear reduction of IGF-I in sera as compared with controls [42], even though the studies were initially expected to exibit increased concentrations, due to the tumourigenic activity of IGF-I. This is not so surprising in that the IGF-I determinations were obtained from sera of subjects already affected with MM. It is known that all cancers, including MM, possess a more or less strong inflammatory component (in particular the proinflammatory cytokines IL-6 and TNF-alpha are produced by BAY 11-7082 ic50 myeloma cells) and that inflammation is associated with reduced IGF-I synthesis [43].